Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Response Biomedical has successfully achieved its analytical sensitivity targets for its flu A test, with results that are in excess of 100 times more sensitive than commercially available rapid influenza A tests.
Subscribe to our email newsletter
This superior level of performance is particularly important as leading public health agencies continue to express caution about the lack of sensitivity and related performance limitations of currently available rapid flu A tests.
Response Biomedical also announced it has initiated development of a separate test to specifically identify only the H5N1 strain, the lethal form of avian flu threatens to cause a global influenza pandemic. Early feasibility testing has produced encouraging results.
“Since announcing our plans on October 24, 2005 to commercialize a high sensitivity flu A test, we have received tremendous interest from government organizations and the private sector,” said Bill Radvak, president and CEO of Response Biomedical. “These same organizations have expressed further interest in the prospect of a RAMP H5N1 test.”
As a result of these expressions of interest, the company is entering into collaborations with several government health organizations and international members of the World Health Organization’s Global Influenza Surveillance Network. The company intends to commercialize the test for both human and animal applications.